Cadila Healthcare is currently trading at Rs. 446.85, up by 3.35 points or 0.76% from its previous closing of Rs. 443.50 on the BSE.
The scrip opened at Rs. 443.20 and has touched a high and low of Rs. 450.40 and Rs. 442.20 respectively. So far 32508 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 329.95 on 26-Dec-2016.
Last one week high and low of the scrip stood at Rs. 454.60 and Rs. 438.05 respectively. The current market cap of the company is Rs. 45781.77 crore.
The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 17.28% and 7.93% respectively.
Cadila Healthcare's wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received the final approval from the United States Food & Drug Administration (USFDA) to market Minocycline Hydrochloride Extended-Release Tablets in strengths of 45 mg, 80 mg, 90 mg, 105 mg, and 135 mg. Zydus also received the tentative approval for Minocycline Hydrochloride Extended-Release Tablets, 55 mg, 65 mg, and 115 mg.
Minocycline Hydrochloride Extended-Release Tablets are a tetracycline-class drug, indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.